Clinical trial · Observational
Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients.
Genetic Variants of Selected Genes Using Target Deep Sequencing in Colo-Rectal Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal cancers (CRC) are the third most common human malignancy, and are also the leading cause of cancer related deaths worldwide. Early detection of premalignant lesions such as adenomatous polyps has decreased the risk of CRCs; however, cases which are initially undetected and progress to advanced CRC with distant metastasis are still unfortunately incurable. The development of CRC is a complex and heterogeneous process arising from an interaction between multiple etiological factors, including genetic factors and environmental factors such as diet and lifestyle. The challenges are to understand the molecular basis of individual susceptibility to colorectal cancer and to determine factors that initiate the development of the tumor, drive its progression, and determine its responsiveness or resistance to antitumor agents. Next generation sequencing(NGS)-driven genomic studies are already reporting novel features of cancer genomes beyond the traditional mutational categories. Recent advance in sequencing technology has enabled comprehensive profiling of genetic alterations in CRC.These methods are facilitating an increase in the efficiency and resolution of detection of each of the principal types of somatic cancer genome alterations, including nucleotide substitutions, small insertions and deletions, copy number alterations, chromosomal rearrangements,DNA methylation sequencing such as bisulfite-sequencing and microbial infections. Besides the microsatellite instability (MSI), some researchers reported novel mitochondrial mutations in the cancer genomes. NGS technology will help the investigators for understanding of entire CRC genomes and the obtained knowledge will lead to a better diagnosis and personalized targeted therapeutics for CRC management
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Colon | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole genome sequencing | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cancer colon with no distant metastasis
- description
- Genetic: Whole genome Sequencing
- interventionNames
- Genetic: Whole genome sequencing
- label
- Cancer colon with distant metastases
- description
- Genetic: Whole genome Sequencing
- interventionNames
- Genetic: Whole genome sequencing
- label
- control group
- description
- Genetic: Whole genome Sequencing
- interventionNames
- Genetic: Whole genome sequencing
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
Show eligibility criteria text
Inclusion Criteria: 1. Ages Eligible for Study: 10 Years and older 2. Genders Eligible for Study: Both 3. Patients who can give informed consent themselves 4. 10 healthy controls will also be included in the study. Exclusion Criteria: 1. Other cancer types rather than CRC. 2. Younger age than 10 years
References
Publications (0)
Data not yet available